Effects of Tocilizumab on Bone Metabolism, RANKL, osteoprotegerin, DKK-1 and osteopontin in Rheumatoid Arthritis.

Effects of Tocilizumab on Bone Metabolism, RANKL, osteoprotegerin, DKK-1 and osteopontin in Rheumatoid Arthritis. - Effects of Biologics DMARDs on Bone Metabolism in Rheumatoid Arthritis.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000016117

Enrollment

Registered

2018-03-31

Start date

2012-03-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Adaptation case by the tocilizumab use guideline of Japan College of Rheumatology.

Exclusion criteria

Exclusion criteria: Case outside the patient who can't get consent in a test and the adaptation by a guideline

Design outcomes

Primary

Measure	Time frame
Serum parameters of bone metabolism, RANKL, osteoprotegerin, DKK-1 and osteopontin after 12 weeks of tocilizumab treatment.	—

Secondary

Measure	Time frame
Disease activity after 12 weeks of tocilizumab treatment.	—

Countries

Japan

Contacts

Public ContactMasayasu Kitano

Hyogo College of Medicine Division of Rheumatology, Department of Internal Medicine

mkitano6@hyo-med.ac.jp0798-45-6591

Outcome results